277 related articles for article (PubMed ID: 19545283)
21. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
22. [Arsenic trioxide as a therapeutic agent in APL].
Emi N
Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
[No Abstract] [Full Text] [Related]
23. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
Spencer A; Firkin F
Aust N Z J Med; 1999 Jun; 29(3):385-6. PubMed ID: 10868510
[No Abstract] [Full Text] [Related]
25. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
[No Abstract] [Full Text] [Related]
26. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
27. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
[No Abstract] [Full Text] [Related]
29. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Sanz MA; Fenaux P; Lo Coco F;
Haematologica; 2005 Sep; 90(9):1231-5. PubMed ID: 16154847
[TBL] [Abstract][Full Text] [Related]
31. Arsenic-based therapy benefits leukemia patients.
FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
[No Abstract] [Full Text] [Related]
32. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
[TBL] [Abstract][Full Text] [Related]
33. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
34. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
35. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
36. Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide.
Au WY; Fung AT; Ma ES; Chan CH; Wong KF; Chim CS; Liang RH; Kwong YL
Br J Haematol; 2005 Dec; 131(5):632-5. PubMed ID: 16351640
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
Yamamoto Y; Sasaki M; Oshimi K; Sugimoto K
Acta Haematol; 2009; 122(1):52-3. PubMed ID: 19816009
[No Abstract] [Full Text] [Related]
38. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Zhang L; Zhao H; Zhu X; Chen Y; Zou Y; Chen X
Pediatr Blood Cancer; 2008 Aug; 51(2):210-5. PubMed ID: 18428427
[TBL] [Abstract][Full Text] [Related]
40. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
Br J Haematol; 2001 Apr; 113(1):257-8. PubMed ID: 11360894
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]